Symbols / AFMDQ $0.00 +0.00% Affimed N.V.

Healthcare • Biotechnology • Germany • PNK
AFMDQ Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO —
Exch · Country PNK · Germany
Market Cap 1.64K
Enterprise Value -11.21M
Income -69.97M
Sales 5.64M
FCF (ttm) -45.39M
Book/sh 1.24
Cash/sh 1.47
Employees 76
Insider 10d —
IPO Sep 12, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E —
PEG —
P/S 0.00
P/B 0.00
P/C —
EV/EBITDA 0.18
EV/Sales -1.99
Quick Ratio 1.71
Current Ratio 1.93
Debt/Eq 74.96
LT Debt/Eq —
EPS (ttm) -5.33
EPS next Y —
EPS Growth —
Revenue Growth -91.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2024-11-14
Earnings (prior) 2024-11-14
ROA -49.42%
ROE -149.49%
ROIC —
Gross Margin 100.00%
Oper. Margin -87.09%
Profit Margin 0.00%
Shs Outstand 16.39M
Shs Float 15.48M
Insider Own 0.00%
Instit Own 0.01%
Short Float 3.75%
Short Ratio 4.60
Short Interest 580.55K
52W High 0.24
vs 52W High -99.96%
52W Low 0.00
vs 52W Low 900.00%
Beta 0.31
Impl. Vol. —
Rel Volume 0.50
Avg Volume 5.18K
Volume 2.60K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.00
Price $0.00
Change 0.00%
About

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-49.84
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-05-14 down HC Wainwright & Co. Buy → Neutral —
2025-05-13 down Wells Fargo Overweight → Equal-Weight $0
2025-05-13 down Leerink Partners Outperform → Market Perform $0
2024-12-12 main Wells Fargo Overweight → Overweight $15
2024-12-10 reit HC Wainwright & Co. Buy → Buy $10
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Total Revenue
8.28
-79.99%
41.35
+2.45%
40.37
Operating Revenue
8.28
-79.99%
41.35
+2.45%
40.37
Operating Expense
119.41
-8.37%
130.33
+23.69%
105.36
Research And Development
94.96
-3.90%
98.81
+21.26%
81.49
Selling General And Administration
24.68
-23.07%
32.08
+32.44%
24.22
General And Administrative Expense
24.68
-23.07%
32.08
+32.44%
24.22
Salaries And Wages
13.05
-14.39%
15.25
+42.34%
10.71
Other Gand A
8.82
-33.85%
13.33
+22.41%
10.89
Other Operating Expenses
-0.22
+60.92%
-0.56
-63.66%
-0.34
Total Expenses
119.41
-8.37%
130.33
+23.69%
105.36
Operating Income
-111.14
-24.91%
-88.97
-36.89%
-65.00
Total Operating Income As Reported
-106.66
-21.04%
-88.12
-37.62%
-64.03
EBITDA
-102.38
-25.66%
-81.47
-46.86%
-55.48
Normalized EBITDA
-103.81
-22.48%
-84.76
-34.04%
-63.24
Reconciled Depreciation
1.75
-39.67%
2.90
+117.32%
1.33
EBIT
-104.13
-23.42%
-84.37
-48.52%
-56.81
Total Unusual Items
1.43
-56.50%
3.29
-57.65%
7.76
Total Unusual Items Excluding Goodwill
1.43
-56.50%
3.29
-57.65%
7.76
Net Income
-105.94
-23.18%
-86.00
-49.51%
-57.52
Pretax Income
-105.94
-23.18%
-86.00
-49.51%
-57.52
Net Non Operating Interest Income Expense
0.24
+118.75%
-1.27
-12.60%
-1.13
Interest Expense Non Operating
1.81
+10.80%
1.63
+128.93%
0.71
Net Interest Income
0.24
+118.75%
-1.27
-12.60%
-1.13
Interest Expense
1.81
+10.80%
1.63
+128.93%
0.71
Interest Income Non Operating
0.51
0.00
0.00
Interest Income
0.51
0.00
0.00
Other Income Expense
4.96
+17.10%
4.24
-50.71%
8.60
Other Non Operating Income Expenses
3.54
+270.93%
0.95
+13.32%
0.84
Gain On Sale Of Security
1.43
-56.50%
3.29
-57.65%
7.76
Tax Provision
0.00
+50.00%
0.00
+0.00%
0.00
Tax Rate For Calcs
0.00
+0.00%
0.00
-22.22%
0.00
Tax Effect Of Unusual Items
0.30
-56.50%
0.69
-67.06%
2.10
Net Income Including Noncontrolling Interests
-105.94
-23.18%
-86.00
-49.51%
-57.52
Net Income From Continuing Operation Net Minority Interest
-105.94
-23.18%
-86.00
-49.51%
-57.52
Net Income From Continuing And Discontinued Operation
-105.94
-23.18%
-86.00
-49.51%
-57.52
Net Income Continuous Operations
-105.94
-23.18%
-86.00
-49.51%
-57.52
Normalized Income
-107.07
-20.84%
-88.60
-40.22%
-63.19
Net Income Common Stockholders
-105.94
-23.18%
-86.00
-49.51%
-57.52
Diluted EPS
-7.09
-18.17%
-6.00
-25.00%
-4.80
Basic EPS
-7.09
-18.17%
-6.00
-25.00%
-4.80
Basic Average Shares
14.94
+4.94%
14.24
+19.13%
11.95
Diluted Average Shares
14.94
+4.94%
14.24
+19.13%
11.95
Diluted NI Availto Com Stockholders
-105.94
-23.18%
-86.00
-49.51%
-57.52
Insurance And Claims
2.80
-19.84%
3.49
+33.68%
2.61
Total Other Finance Cost
-1.53
-325.21%
-0.36
-186.99%
0.41
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Total Assets
97.16
-51.55%
200.51
-10.94%
225.13
Current Assets
84.19
-57.06%
196.07
-5.00%
206.39
Cash Cash Equivalents And Short Term Investments
72.90
-61.69%
190.29
-3.72%
197.63
Cash And Cash Equivalents
38.53
-79.75%
190.29
-3.72%
197.63
Cash Equivalents
11.90
0.00
—
Cash Financial
26.63
-86.01%
190.29
—
Other Short Term Investments
34.37
0.00
—
Receivables
5.33
+97.52%
2.70
-43.92%
4.81
Accounts Receivable
5.33
+97.52%
2.70
-43.92%
4.81
Inventory
0.46
-26.27%
0.63
+49.17%
0.42
Other Current Assets
5.50
+123.67%
2.46
-30.42%
3.53
Total Non Current Assets
12.97
+191.96%
4.44
-76.30%
18.74
Net PPE
12.94
+195.26%
4.38
-8.40%
4.79
Gross PPE
16.03
+86.05%
8.61
+2.95%
8.37
Accumulated Depreciation
-3.08
+27.14%
-4.23
-18.12%
-3.58
Properties
0.00
0.00
0.00
Buildings And Improvements
8.04
+1372.34%
0.55
—
Machinery Furniture Equipment
7.93
-0.74%
7.99
+9.19%
7.32
Other Properties
—
0.56
-42.28%
0.97
Leases
0.05
-29.73%
0.07
+0.00%
0.07
Goodwill And Other Intangible Assets
0.03
-56.90%
0.06
-96.39%
1.61
Other Intangible Assets
0.03
-56.90%
0.06
-96.39%
1.61
Investments And Advances
—
0.00
-100.00%
12.35
Total Liabilities Net Minority Interest
39.35
-17.33%
47.60
-46.63%
89.18
Current Liabilities
25.91
-25.23%
34.65
-46.32%
64.55
Payables And Accrued Expenses
18.92
-0.84%
19.08
+1.15%
18.86
Payables
18.92
-0.84%
19.08
+1.15%
18.86
Accounts Payable
18.92
-0.84%
19.08
+1.15%
18.86
Current Debt And Capital Lease Obligation
6.37
+0.73%
6.33
+400.87%
1.26
Current Debt
5.83
-1.64%
5.93
+922.41%
0.58
Other Current Borrowings
5.83
-1.64%
5.93
+922.41%
0.58
Current Capital Lease Obligation
0.54
+36.11%
0.40
-42.02%
0.68
Current Deferred Liabilities
0.62
-93.31%
9.25
-79.18%
44.42
Current Deferred Revenue
0.62
-93.31%
9.25
-79.18%
44.42
Total Non Current Liabilities Net Minority Interest
13.44
+3.84%
12.95
-47.45%
24.64
Long Term Debt And Capital Lease Obligation
12.98
+9.41%
11.86
-31.93%
17.43
Long Term Debt
6.32
-45.93%
11.69
-31.49%
17.06
Long Term Capital Lease Obligation
6.66
+3684.09%
0.18
-52.17%
0.37
Non Current Deferred Liabilities
0.46
-57.16%
1.08
-84.98%
7.21
Non Current Deferred Revenue
0.46
-57.16%
1.08
-84.98%
7.21
Stockholders Equity
57.81
-62.20%
152.91
+12.48%
135.95
Common Stock Equity
57.81
-62.20%
152.91
+12.48%
135.95
Capital Stock
1.50
+0.47%
1.49
+20.99%
1.23
Common Stock
1.50
+0.47%
1.49
+20.99%
1.23
Share Issued
15.00
+0.43%
14.93
+21.00%
12.34
Ordinary Shares Number
15.00
+0.43%
14.93
+21.00%
12.34
Retained Earnings
-536.13
-24.63%
-430.19
-29.03%
-333.40
Gains Losses Not Affecting Retained Earnings
592.43
+1.86%
581.61
+24.25%
468.11
Other Equity Adjustments
592.43
+1.86%
581.61
+24.25%
468.11
Total Equity Gross Minority Interest
57.81
-62.20%
152.91
+12.48%
135.95
Total Capitalization
64.13
-61.04%
164.60
+7.58%
153.01
Working Capital
58.28
-63.89%
161.42
+13.80%
141.85
Invested Capital
69.96
-58.98%
170.53
+11.03%
153.59
Total Debt
19.35
+6.39%
18.19
-2.69%
18.69
Capital Lease Obligations
7.20
+1158.57%
0.57
-45.58%
1.05
Net Tangible Assets
57.78
-62.20%
152.86
+13.78%
134.34
Tangible Book Value
57.78
-62.20%
152.86
+13.78%
134.34
Investmentin Financial Assets
—
0.00
-100.00%
12.35
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-110.27
-5.13%
-104.89
-21.13%
-86.59
Cash Flow From Continuing Operating Activities
-110.27
-5.13%
-104.89
-21.13%
-86.59
Net Income From Continuing Operations
-105.94
-23.18%
-86.00
-49.51%
-57.52
Depreciation Amortization Depletion
1.75
-39.67%
2.90
+117.32%
1.33
Depreciation
1.72
—
—
Amortization Cash Flow
0.03
—
—
Depreciation And Amortization
1.75
-39.67%
2.90
+117.32%
1.33
Amortization Of Intangibles
0.03
—
—
Other Non Cash Items
-0.73
+65.71%
-2.12
+67.48%
-6.51
Stock Based Compensation
10.71
-43.94%
19.11
+61.68%
11.82
Deferred Tax
0.00
+50.00%
0.00
+0.00%
0.00
Deferred Income Tax
0.00
+50.00%
0.00
+0.00%
0.00
Operating Gains Losses
-4.26
—
—
Gain Loss On Sale Of PPE
0.08
0.00
0.00
Change In Working Capital
-12.16
+68.05%
-38.07
-9.36%
-34.81
Change In Receivables
1.09
-48.27%
2.11
+189.19%
-2.37
Change In Inventory
0.10
+148.31%
-0.21
-18.29%
-0.17
Change In Payables And Accrued Expense
-9.77
+76.21%
-41.05
-36.87%
-29.99
Change In Payable
-9.77
+76.21%
-41.05
-36.87%
-29.99
Change In Account Payable
-9.77
+76.21%
-41.05
-36.87%
-29.99
Change In Other Current Assets
-3.59
-433.77%
1.07
+147.27%
-2.27
Investing Cash Flow
-36.06
-743.34%
5.61
+245.58%
-3.85
Cash Flow From Continuing Investing Activities
-36.06
-743.34%
5.61
+245.58%
-3.85
Net PPE Purchase And Sale
-3.73
-465.86%
-0.66
+69.99%
-2.20
Purchase Of PPE
-3.73
-465.86%
-0.66
+69.99%
-2.20
Capital Expenditure
-3.73
-435.78%
-0.70
+81.92%
-3.85
Net Investment Purchase And Sale
-33.31
-628.61%
6.30
0.00
Purchase Of Investment
-34.25
0.00
0.00
Sale Of Investment
0.94
-85.11%
6.30
0.00
Net Business Purchase And Sale
0.98
0.00
0.00
Gain Loss On Sale Of Business
-4.34
0.00
0.00
Net Intangibles Purchase And Sale
0.00
+100.00%
-0.04
+97.76%
-1.65
Purchase Of Intangibles
0.00
+100.00%
-0.04
+97.76%
-1.65
Financing Cash Flow
-6.22
-107.02%
88.56
-33.71%
133.58
Cash Flow From Continuing Financing Activities
-6.22
-107.02%
88.56
-33.71%
133.58
Net Issuance Payments Of Debt
-6.42
-388.96%
-1.31
-107.80%
16.84
Issuance Of Debt
0.00
0.00
-100.00%
17.50
Repayment Of Debt
-6.42
-388.96%
-1.31
-100.15%
-0.66
Long Term Debt Issuance
0.00
0.00
-100.00%
17.50
Long Term Debt Payments
-6.42
-388.96%
-1.31
-100.15%
-0.66
Net Long Term Debt Issuance
-6.42
-388.96%
-1.31
-107.80%
16.84
Net Common Stock Issuance
0.23
-99.75%
95.91
-22.94%
124.46
Net Other Financing Charges
-0.04
+99.42%
-6.04
+21.83%
-7.72
Changes In Cash
-152.55
-1321.70%
-10.73
-124.87%
43.14
Effect Of Exchange Rate Changes
0.79
-76.64%
3.39
-55.66%
7.64
Beginning Cash Position
190.29
-3.72%
197.63
+34.58%
146.85
End Cash Position
38.53
-79.75%
190.29
-3.72%
197.63
Free Cash Flow
-114.00
-7.96%
-105.59
-16.75%
-90.44
Common Stock Issuance
0.23
-99.75%
95.91
-22.94%
124.46
Interest Paid CFO
-1.39
-9.08%
-1.28
-41.10%
-0.91
Interest Received CFO
1.74
+209.04%
0.56
0.00
Issuance Of Capital Stock
0.23
-99.75%
95.91
-22.94%
124.46
Sale Of Business
0.98
0.00
0.00
Taxes Refund Paid
-0.00
-50.00%
-0.00
+0.00%
-0.00
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category